目的： 探究麝香保心丸联合沙库巴曲缬沙坦钠治疗急性心肌梗死经皮冠状动脉介入（percutaneous coronary intervention, PCI）治疗术后的临床效果。方法： 选取滁州市第一人民医院2021年1月—2023年11月收治的120例急性心肌梗死PCI术后患者,按随机数字表法分为观察组60例和对照组60例。对照组患者予以抗凝、抗血小板、调脂等常规治疗基础上加用沙库巴曲缬沙坦钠，观察组在常规治疗的基础上加用沙库巴曲缬沙坦钠联合麝香保心丸治疗。比较2组患者治疗前后C反应蛋白（C-reactive protein, CRP）、氨基末端脑利尿钠肽前体（N-terminal pro-brain natriuretic peptide, NT-proBNP）、血压、左室舒张末期内径(left ventricular end-diastolic diameter, LVEDD)、左室收缩末期内径(left ventricular end-systolic diameter, LVESD)、左室短轴缩短率（fractional shortening, FS）、左室射血分数（left ventricular ejection fraction, LVEF），比较2组住院期间心律失常的发生率、住院时间及6个月内因心脏不良事件再住院率。结果： 治疗4周后,观察组患者血清CRP、NT-proBNP水平均较治疗前显著降低(均P<0.05)；治疗6个月后，观察组心脏彩色超声指标（LVEDD、LVESD、FS、LVEF）改善优于对照组（均P<0.05）；住院期间观察组房性、室性心律失常的发生率低于对照组(均P<0.05)，住院时间观察组短于对照组(P<0.05)。随访6个月，再住院率观察组较对照组低（5.1%比26.3%，P<0.05）。结论： 麝香保心丸联合沙库巴曲缬沙坦钠治疗急性心肌梗死PCI术后患者能有效抑制炎症反应，逆转心室重构，改善心功能，减少并发症的发生，改善预后。

Objective To investigate the clinical effect of Shexiang Baoxin pill combined with sacubitril/valasrtan in the treatment of acute myocardial infarction after percutaneous coronary intervention(PCI).Methods A total of 120 patients with acute myocardial infarction from January 2021 to November 2023 after PCI were selected and randomly assigned to observation group (60 cases) and control group (60 cases) in Chuzhou First People’s Hospital. The patients in both groups were given anticoagulation, antiplatelet, lipid-regulating, and other conventional treatment, while the control group was treated with sacubitril/valsartan, and the observation group was treated with sacubitril/valsartan combined with Shexiang Baoxin pill. The indexes including the changes of C-reactive protein(CRP), N-terminal pro-brain natriuretic peptide (NT-proBNP), blood pressure, left ventricular end-diastolic diameter(LVEDD), left ventricular end-systolic diameter(LVESD), fractional shortening(FS) rate, left ventricular ejection fraction (LVEF) were compared between the two groups. The incidence of arrhythmia and length of stay during hospitalization and the rate of re-hospitalization within six months due to adverse cardiac events were also compared between the two groups. Results After 4-week treatment, the levels of CRP and NT-proBNP in the observation group were significantly lower than those in the control group (all P<0.05). After 6-month treatment, the cardiac color ultrasound ultrasonography indexes (LVEDD, LVESD, FS, LVEF) in the observation group were better than those in the control group (all P<0.05). The incidence of atrial and ventricular arrhythmias in the observation group was lower than that in the control group duration of hospital stay (P<0.05), and length of hospitalization in the observation group was shorter than that in the control group (P<0.05). At the 6-month follow-up, the rate of rehospitalization in the observation group was lower than that in the control group (5.1% vs 26.3%, P<0.05).Conclusions The combination of Shexiang Baoxin pill and sacubitri/valsartan can effectively inhibit inflammatory response, reverse ventricular remodeling, improve cardiac function, reduce complications and improve prognosis in patients with acute myocardial infarction after PCI.